Centiva Capital LP Acquires Shares of 7,550 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Centiva Capital LP acquired a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,550 shares of the company's stock, valued at approximately $605,000.

Several other institutional investors have also made changes to their positions in the company. Westfield Capital Management Co. LP acquired a new stake in PROCEPT BioRobotics during the 3rd quarter worth about $72,563,000. Chicago Capital LLC purchased a new stake in shares of PROCEPT BioRobotics in the second quarter worth approximately $14,233,000. Federated Hermes Inc. boosted its holdings in shares of PROCEPT BioRobotics by 788.9% during the second quarter. Federated Hermes Inc. now owns 183,420 shares of the company's stock worth $11,205,000 after purchasing an additional 162,785 shares during the period. Transatlantique Private Wealth LLC acquired a new stake in shares of PROCEPT BioRobotics during the second quarter worth approximately $9,164,000. Finally, M&G Plc acquired a new position in PROCEPT BioRobotics in the 2nd quarter valued at approximately $8,507,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the sale, the chief executive officer now owns 152,762 shares in the company, valued at $14,851,521.64. The trade was a 14.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 25,000 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the completion of the sale, the chief financial officer now directly owns 96,096 shares in the company, valued at $6,964,077.12. This trade represents a 20.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 594,183 shares of company stock valued at $53,258,164 in the last quarter. Corporate insiders own 17.40% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PRCT shares. Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an "overweight" rating and a $105.00 target price for the company. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Piper Sandler reissued an "overweight" rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. Finally, TD Cowen increased their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, September 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $97.86.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT traded up $1.23 during mid-day trading on Friday, hitting $94.84. 403,797 shares of the company's stock traded hands, compared to its average volume of 626,316. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $85.56 and a two-hundred day moving average of $74.75. The firm has a market capitalization of $4.95 billion, a price-to-earnings ratio of -48.64 and a beta of 0.99. PROCEPT BioRobotics Co. has a 12 month low of $36.99 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company had revenue of $58.40 million for the quarter, compared to the consensus estimate of $53.30 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. The business's revenue was up 66.4% compared to the same quarter last year. On average, equities analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).